News List

Hyderabad’s Sajjala Bio to begin clinical trials on diabetes drug


Sajjala Bio Labs has successfully completed preclinical toxicology studies for recombinant liraglutide, a drug used for the treatment of type-2 diabetes and obesity.

By Team ABLE

Hyderabad-based Sajjala Bio Labs has successfully completed preclinical toxicology studies for recombinant liraglutide, a drug used for the treatment of type-2 diabetes and obesity. Novo Nordisk, which markets the product under the brand name Victoza, held the patent for this drug till September. 

The company is aiming to complete the clinical trials and launch generic liraglutide by December next year or so, director Bhargava Sajjala said. Its vision is to develop cost-effective bio-generics of complex molecules and strategy is to focus primarily on India and other semi-regulated and less-regulated markets.